Sulthiame vs phenytoin
Rash · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in rash compared with phenytoin (low certainty).
1 finding from 1 review
- RR 0.28 [0.02, 4.36]1 study · 146 participantsLow
Findings
What do systematic reviews say?
283 questions · 285 findings · 33 reviews · Epilepsy
No studies found 31 · 10.9%GRADE not reported 13 · 4.6%Very low 33 · 11.6%Low 80 · 28.1%Moderate 96 · 33.7%High 32 · 11.2%
Sulthiame vs phenytoin
Gingival hyperplasia · participants with epilepsy (GTCS)
Sulthiame may leads to lower gingival hyperplasia compared with phenytoin (low certainty).
1 finding from 1 review
- RR 0.03 [0, 0.58]1 study · 146 participantsLow
Sulthiame vs phenytoin
Other · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in other compared with phenytoin (low certainty).
1 finding from 1 review
- RR 1.4 [0.17, 11.59]1 study · 146 participantsLow
Sulthiame vs placebo
All adverse effects · people with epilepsy
1 finding from 1 review
- no estimate extracted2 studies · 100 participantsGRADE not reported
Sulthiame vs levetiracetam
Treatment withdrawal · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in treatment withdrawal compared with levetiracetam (low certainty).
1 finding from 1 review
- RR 0.32 [0.1, 1.03]1 study · 43 participantsLow
Sulthiame vs levetiracetam
Seizure freedom · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in seizure freedom compared with levetiracetam (low certainty).
1 finding from 1 review
- RR 1.12 [0.88, 1.44]1 study · 43 participantsLow
Sulthiame vs levetiracetam
Adverse effects (general symptoms) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).
1 finding from 1 review
- RR 1.08 [0.76, 1.54]1 study · 43 participantsLow
Sulthiame vs levetiracetam
Adverse effects (central nervous system) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (central nervous system) compared with levetiracetam (low certainty).
1 finding from 1 review
- RR 1.17 [0.77, 1.79]1 study · 43 participantsLow
Sulthiame vs levetiracetam
Adverse effects (behaviour) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (behaviour) compared with levetiracetam (low certainty).
1 finding from 1 review
- RR 0.95 [0.59, 1.55]1 study · 43 participantsLow
Sulthiame vs levetiracetam
Adverse effects (airways) · participants with epilepsy (BECTS)
Sulthiame may leads to higher adverse effects (airways) compared with levetiracetam (low certainty).
1 finding from 1 review
- RR 2.67 [1.17, 6.12]1 study · 43 participantsLow
Carisbamate vs placebo
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.36 [1.14, 1.62]4 studies · 2211 participantsModerate
Carisbamate vs placebo
Seizure freedom · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes seizure freedom compared with placebo (very low certainty).
1 finding from 1 review
- RR 2.43 [0.84, 7.03]1 study · 540 participantsVery low
Carisbamate vs placebo
Treatment withdrawal · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.32 [0.82, 2.12]4 studies · 2211 participantsVery low
Carisbamate vs placebo
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.8 [0.78, 4.17]4 studies · 2211 participantsVery low
Carisbamate vs placebo
Participants who experienced any adverse event Adverse event regardless of severity · people with drug‐resistant focal epilepsy
Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).
1 finding from 1 review
- RR 1.1 [0.93, 1.3]2 studies · 1084 participantsLow
Carisbamate vs placebo
Dizziness · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).
1 finding from 1 review
- RR 2.06 [1.23, 3.44]4 studies · 2211 participantsVery low
Carisbamate vs placebo
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
- RR 1.82 [1.28, 2.58]4 studies · 2211 participantsLow
Zonisamide vs placebo
50% responder rate · people with focal epilepsy
Zonisamide probably leads to higher 50% responder rate (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.86 [1.6, 2.17]7 studies · 1429 participantsModerate
Zonisamide vs placebo
Withdrawal rates ‐ Any dose · people with focal epilepsy
Zonisamide probably leads to higher withdrawal rates (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.44 [1.08, 1.93]6 studies · 1156 participantsModerate
Zonisamide vs placebo
Ataxia · people with focal epilepsy
Zonisamide may leads to higher adverse effects: ataxia (whole treatment period; any dose) compared with placebo (low certainty).
1 finding from 1 review
- RR 3.854 studies · 734 participantsLow